Butrum

Quick links to important sections

Butrum

Method of action: Analgesic, Antitussive, Sedative

Treatment option: Anesthesia, Pain, Pain Management

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Butrum

Quick Facts

Property Description
Active Ingredient Butorfanol (Butorphanol)
Primary Forms Injectable solution, Nasal spray
Pharmacological Class Opioid analgesic
General Purpose Management of moderate to severe pain
Origin Synthetic (Morphinan derivative)

Butrum: Definition and Pharmacological Class

Butrum is a powerful, prescription-only medication whose active component is Butorfanol, primarily used in medicine to provide relief from moderate to severe pain. Its classification as a synthetic opioid analgesic signifies that it is a manufactured compound designed to act upon the body’s central nervous system for pain suppression. Butorfanol is characterized by its unique profile as an opioid agonist-antagonist. This dual mechanism—activating some pain receptors while partially inhibiting others—is the key feature differentiating its specific effect from pure opioid agonists. Its chemical structure is that of a morphinan derivative, a type of compound frequently investigated for its potent and rapid analgesic properties.

The Active Compound and Physical Forms

Butrum’s efficacy relies on the single, specific active ingredient, Butorfanol, often stabilized as butorphanol tartrate for optimal delivery. This single-ingredient approach ensures focused therapeutic action. Butorfanol is notable for its availability in two distinct forms: an injectable solution for swift parenteral delivery and a nasal spray formulation. This dual presentation offers clinicians flexibility in providing pain relief, such as administering the injectable solution during surgical procedures or utilizing the nasal spray when rapid, non-invasive systemic relief is required. The aqueous base of these preparations is essential for ensuring efficient absorption of the active substance into the body via the designated routes of administration.

What side effects are possible with Butrum?

Adverse Reaction Classification

Butrum’s official safety profile is organized by its effects on the body's systems, with many adverse reactions being centrally mediated. The most frequently documented side effects are categorized as Very Common in regulatory documents (ge 10% incidence), including somnolence (drowsiness) and dizziness. Effects such as nausea, vomiting, headache, constipation, and hypertension are classified as Common (1% to 10%). These reactions primarily fall under the Nervous System, Gastrointestinal, and Cardiovascular System-Organ Classes (SOCs).

Serious Adverse Reactions and Safety Restrictions

Regulatory agencies highlight the potential for Life-Threatening Respiratory Depression as the primary serious risk associated with this opioid analgesic, with the highest risk documented upon the initiation of therapy or after a dosage increase. Other serious concerns include the inherent opioid class risks of Addiction, Abuse, and Misuse, the potential for Serotonin Syndrome when used with certain other medications, and the risk of Neonatal Opioid Withdrawal Syndrome from prolonged maternal use during pregnancy.

Population and Exposure Safety Notes

Specific safety considerations are officially noted for certain patient groups. Individuals with hepatic or renal impairment may experience significantly greater exposure to the medication. Due to its unique mechanism, use in patients with established opioid dependence may precipitate withdrawal symptoms. Regulatory labeling also restricts use in patients with pre-existing conditions like acute or severe bronchial asthma and gastrointestinal obstruction.

Regulatory Safety Summary

  • The most frequently reported adverse reactions are centrally mediated, with drowsiness and dizziness classified as Very Common.
  • The most critical, serious risk is Life-Threatening Respiratory Depression, which is time-dependent, posing the greatest danger at the start of treatment.
  • The medication carries the documented risks of Addiction, Abuse, and Misuse inherent to controlled substances, and requires specific precautions for those with hepatic impairment.

The official safety information structurally emphasizes the potential for CNS and respiratory impairment, categorizing risks by frequency and duration to clearly delineate the high-level safety constraints of the medication.

Overdose and Emergency Response

Overdose involving Butorphanol is documented as an acute medical emergency that may result in life-threatening or fatal outcomes, particularly due to severe respiratory depression. Immediate medical attention or contact with emergency services (911) is required if an overdose is known or suspected.

Official regulatory documents state that an overdose typically presents with profound central nervous system (CNS) effects. These include somnolence that can progress to stupor or coma, along with deep sedation, skeletal muscle flaccidity, and constricted pupils (miosis). Severe or life-threatening manifestations include respiratory arrest, pulmonary edema, and cardiovascular events like hypotension and cardiac arrhythmias. Accidental exposure, particularly in children, is noted as a significant risk that can result in a fatal overdose.

The documented emergency procedures prioritize the reestablishment of a patent and protected airway and the institution of assisted or controlled ventilation. The specific antidotes, naloxone or nalmefene, are used to reverse respiratory depression. Supportive care involves administering oxygen and using vasopressors as needed. Following antidote administration, careful monitoring is required, as the drug's duration of action may be longer than the antagonist's reversal effect.

Therapeutic Uses of Butrum

Butrum is a medication primarily used for managing severe pain where supportive symptom management is appropriate, and is considered relevant in acute clinical settings. It is commonly used to help with pain severe enough to require an opioid. It is applied across therapeutic domains involving heightened symptoms, including pain management following surgical procedures, symptoms related to acute trauma, supportive symptomatic management during labor and delivery, and conditions involving episodic or fluctuating manifestations like migraine and colic.


Quick Fact: Butrum: Focus on High-Intensity Symptoms


This medication plays a role in managing conditions characterized by periods of heightened discomfort, offering symptomatic relief when symptoms create noticeable physiological strain. It is commonly used when short-term symptomatic assistance is needed, such as in emergency or perioperative settings. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. Its use contributes to easing the overall symptom load during periods of heightened symptoms.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Butrum (Butorphanol) eligibility is defined by official regulatory documentation, primarily establishing which populations are contraindicated and which require conditional use.

Populations For Whom Use Is Contraindicated

Butrum must not be used in patients with a known hypersensitivity to the drug or any component, or those with significant respiratory depression or severe bronchial asthma in an unmonitored setting. Use is also contraindicated in patients with known or suspected gastrointestinal obstruction (including paralytic ileus) and those with opioid dependence, due to the risk of precipitating acute withdrawal syndrome.

Age and Condition-Based Restrictions

Category Official Regulatory Status
Pediatric Use Not Established (under 18 years of age).
Geriatric Use Use with caution; may require lower initial doses.
Organ Impairment Caution required for hepatic or renal impairment.

Pregnancy and Lactation Eligibility

Use is not recommended during breastfeeding as Butrum is excreted into human milk. Prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome. Acute use during labor and delivery is indicated under close monitoring.

What should I know about interactions with other medicines?

Butrum Interactions with other medicines and products

Official government regulatory documents classify Butrum (Butorphanol) interactions into several domains, primarily focusing on pharmacodynamic and pharmacokinetic effects.

Interaction Scope Key Information from Regulatory Documents
Pharmacodynamic Interactions Concomitant use with CNS Depressants (including Alcohol, Benzodiazepines, Antipsychotics, and other Opioids) results in an additive pharmacologic effect, increasing the risk of profound sedation. Serotonergic drugs (e.g., SSRIs, Triptans) increase the risk of Serotonin Syndrome.
Pharmacokinetic Interactions Butorphanol is metabolized by the CYP3A4 enzyme system. Co-administration with CYP3A4 Inhibitors (e.g., Erythromycin) may increase butorphanol plasma concentrations. Physicians are advised to be alert to the possibility that clearance may be reduced.
Contraindicated Combinations The use of Butorphanol in patients physically dependent on Pure Opioid Agonists is restricted due to the risk of precipitating acute opioid withdrawal. The combination with Alvimopan is also formally contraindicated.

Timing-based interaction rules apply to certain combinations; for instance, some regulatory labels advise avoiding use with MAO Inhibitors (Monoamine Oxidase Inhibitors) or within 14 days of stopping such therapy. Furthermore, official product information explicitly notes that clearance is significantly reduced in populations with hepatic or renal impairment, leading to prolonged drug exposure.

Mechanism of Action

Butrum (Butorphanol) acts as a mixed opioid agonist-antagonist, primarily targeting receptors within the central nervous system. Its core molecular interactions involve two specific G-protein coupled opioid receptors: the mu-opioid receptor (mu-OR) and the kappa-opioid receptor (kappa-OR).

Butorphanol functions as an agonist at the kappa-OR and as a partial agonist/antagonist at the mu-OR. Agonism at the kappa-OR initiates an intracellular signaling cascade that includes the inhibition of adenylate cyclase, resulting in decreased intracellular cyclic adenosine monophosphate (cAMP). This action also promotes the opening of potassium channels and the inhibition of voltage-gated calcium channels, leading to neuronal hyperpolarization. This hyperpolarization reduces neuronal excitability and suppresses the transmission of afferent signals in ascending pathways within the spinal cord and brain. The resulting system-level consequence is modulation of sensory signal processing.

In addition, mu-OR antagonism contributes to modulation of the endogenous opioid system's overall effect on cellular signaling.

Dosage and Administration Information

How to Use Butrum

Butrum (butorphanol) administration is categorized by three routes: Intravenous (IV) injection, Intramuscular (IM) injection, and the Nasal Spray formulation. The injectable forms are typically administered in supervised medical settings, while the nasal spray offers a rapid, non-invasive method for systemic delivery.

Standard Dosing and Frequency

The adult starting dose for IV injection is typically 1 mg, and the standard initial dose for IM injection is 2 mg. The nasal spray is initiated with either a 1 mg dose (one spray in one nostril) or a 2 mg dose (one spray in each nostril) for severe pain. The medication is intended for as-needed (PRN) use, with doses generally repeated every 3 to 4 hours.

Administration Instructions and Adjustments

The nasal spray unit requires full priming before its first use and must be reprimed if it has not been used for 48 hours or longer. Patients receiving the 2 mg nasal dose typically remain recumbent immediately after administration. If a dose is missed, the next dose is taken at the usual scheduled time.

Dose modifications are utilized for specific patient populations. For older adults and individuals with hepatic or renal impairment, the initial dose is reduced (often by 50%), and the interval between repeat doses is extended to at least 6 hours. When discontinuing the medication in physically dependent individuals, the dosage is gradually tapered over a period of days.

Recent Clinical Evidence

Research evidence / Overview of Studies for Butrum


Evidence for Use in Acute Postoperative Pain Management

Butrum was evaluated in research exploring how symptoms change over time immediately following surgical procedures. These studies primarily involved Randomized Controlled Trials (RCTs), many of which were summarized in meta-analyses. Findings describe patterns observed in the studies, often including pain intensity scores that were measured during the first 24 to 48 hours post-surgery. Research has explored administration through routes such as Patient-Controlled Analgesia (PCA) systems, where studies monitored the total consumption of pain medication compared to other treatments.

However, because Butrum was studied for short-term, acute relief, follow-up durations were limited in most trials. Long-term effects are not fully established, and evidence quality varies across studies when Butrum was compared directly to certain other pure opioid medicines in specific pain models.


Research on Pain Management During Labor

Butrum was observed in research exploring short-term symptom changes in women during labor. These research scenarios included clinical trials and prospective studies that focused on outcomes related to physical discomfort. Studies reported measurements of how symptoms evolved in the observed populations, including pain intensity scores following administration. Researchers also monitored outcomes related to systemic or functional imbalance in the mother and outcomes describing episodic or acute changes in the newborn to characterize the setting.

This evidence often derives from older trials and smaller prospective studies. Consequently, sample sizes were modest compared to contemporary large-scale research, and certainty remains low in certain areas.


Studies in the Perioperative and Anesthesia Setting

Butrum was studied for its use as a pre-anesthetic or supplement during the anesthetic process. The research examined temporary physiological imbalance and monitored outcomes such as hemodynamic stability and post-anesthesia conditions like Postoperative Shivering and Emergence Agitation (EA). Studies monitored outcomes capturing phases of heightened symptom activity, and findings describe patterns observed in the studies.

However, the results apply only to the populations studied, and evidence is limited for some specific post-anesthesia outcomes, such as impact on longer-term cognitive function.

Key Studies & References

  1. Butorphanol premedication improves postoperative lung function and analgesic outcomes in laparoscopic surgery: a randomized dose-response study
  2. Impact of butorphanol versus sufentanil on postoperative cognition and inflammation in elderly: a pilot study
  3. Efficacy of intravenous butorphanol for preventing epidural-related maternal fever in women undergoing vaginal delivery: A randomized controlled, double-blind study
  4. Transnasal butorphanol in the emergency department management of migraine headache
  5. Butorphanol Tartrate Nasal Spray Prescribing Information (DailyMed/FDA)

Frequently Asked Questions (FAQ)

Common questions about Butrum (FAQ)

Q: Is Butrum considered a pain reliever?

Yes, regulatory documents indicate that Butrum is an opioid analgesic that is used for the management of pain where a medication in this class is considered appropriate. It is a powerful, prescription-only medication.


Q: Is Butrum the same type of drug as [Another well-known drug]?

Butrum (butorphanol) is classified as a synthetic opioid analgesic with a unique mechanism. Official information describes it as having a mixed action, meaning it acts as an agonist on some opioid receptors and a partial agonist/antagonist on others. This mixed profile is a key difference from pure opioid agonists.


Q: How long does it typically take for Butrum to start working?

According to official product information, the onset of pain relief following administration of the nasal spray is generally within 15 minutes. Injectable forms are typically associated with a faster onset of action.


Q: What are the rare but serious side effects of Butrum?

The most critical risk highlighted in regulatory warnings is life-threatening respiratory depression (slowed or stopped breathing), particularly when treatment begins or the dose is increased. Other serious risks include addiction, abuse, misuse, severe allergic reactions (anaphylaxis), and the possibility of Serotonin Syndrome when used with certain other medications.


Q: Can Butrum affect sleep patterns?

Official information indicates that Butrum can affect rest and sleep. Somnolence (drowsiness) is classified as a very common side effect. Additionally, insomnia (difficulty sleeping) is also listed as a commonly reported reaction in official safety data.


Q: Is Butrum addictive or habit-forming?

Butrum is an opioid analgesic and, like all medications in this class, carries the inherent risks of addiction, abuse, and misuse, even when used as prescribed. The product label also notes the risk of physical dependence.


Q: How quickly does Butrum leave the body after stopping it?

The time it takes for a medication to leave the body is often related to its half-life. Official pharmacokinetic data indicates that the terminal elimination half-life of butorphanol is approximately 4.5 to 5.6 hours in healthy individuals.


Q: Can Butrum be used during lactation?

Official labeling advises caution regarding use during breastfeeding because the medication is known to be excreted into human milk. Regulatory labeling suggests that infants whose mothers are using the drug be monitored for signs of effects, such as increased sleepiness, difficulty breathing, or limpness.


Q: Does Butrum affect blood sugar levels?

Official regulatory information on the drug class indicates that opioids, as a class, may influence the endocrine system. They can be associated with stimulating the pancreatic secretion of hormones like insulin and glucagon, which are involved in regulating blood sugar.


Q: Can Butrum cause weight changes?

Official safety data indicates that weight loss has been reported as a less common side effect in clinical trials. Concerns about weight changes while using any medication are best addressed by a qualified healthcare professional.


Q: What are the long-term effects associated with using Butrum?

Long-term use of opioid medications like Butrum may affect the body’s hormone system, potentially leading to androgen deficiency (a low level of male hormones). Official information also notes a risk of reduced fertility in both males and females from prolonged opioid use.


Q: Is Butrum ever prescribed for children?

Official product information states that the safety and effectiveness in pediatric patients (individuals under 18 years of age) have not been established. The label also carries a warning that accidental exposure to the drug in children can lead to a fatal overdose.


Q: Do any common foods or supplements interfere with Butrum's effectiveness?

The official drug labeling focuses primarily on drug-drug interactions. While specific interactions with common foods or non-prescription supplements are not individually listed, it is generally recommended that patients inform their healthcare provider about all substances and supplements being taken.


Q: Can Butrum affect mood?

Yes, because Butrum is centrally active, official adverse reaction reports include various mood changes. These can include feelings such as anxiety, nervousness, and euphoria (an unusual sense of well-being). Less commonly, depression has also been reported.


Q: Is it normal to feel a slight headache when first starting Butrum?

Headache is listed as a common adverse reaction in official safety reports, meaning it was reported by 1% to 10% of patients during clinical trials. Because it is a common effect, it is a known adverse reaction that may be experienced upon initiation of the medication.


Q: Is there a risk of rebound symptoms if I stop taking Butrum suddenly?

For individuals who have developed a physical dependence on Butrum, abruptly stopping the medication can precipitate an opioid withdrawal syndrome. Regulatory guidance specifies that the dosage must be gradually tapered when discontinuing use in these patients to mitigate withdrawal effects, which can include symptoms like anxiety and trouble sleeping.


Q: Does Butrum show up on a standard drug test?

Butrum is classified by government authorities as a Schedule IV controlled substance. Because it is an opioid analgesic, it may be specifically screened for in drug tests designed to detect the presence of controlled or prescription substances.


Q: Is it normal for Butrum to cause sweating?

Official adverse reaction reports indicate that sweating (diaphoresis) has been reported as a less common side effect. This means it occurred in a smaller percentage of patients during studies.


Q: Can Butrum interfere with driving or operating machinery?

Official patient information explicitly warns that Butrum may impair the mental or physical abilities required to perform potentially hazardous tasks. Regulatory guidance advises patients to avoid these activities until they are certain how the medication affects their mental and physical abilities.


Q: Why is Butrum sometimes considered a "specialized" medication?

Butrum's classification as a potent, prescription-only opioid analgesic gives it a specialized profile. This is largely due to its mixed agonist-antagonist mechanism on opioid receptors, differentiating it pharmacologically from many other pain relief options.


Q: Is it possible to be allergic to Butrum?

Yes, official regulatory documents list a known hypersensitivity to Butrum or any of its components as a contraindication for use. Furthermore, there have been reports of severe allergic reactions (anaphylaxis) following its use.


Q: Are there any warnings about using Butrum with herbal supplements?

The official documentation does not list specific interactions with individual herbal supplements. However, patients are generally advised to disclose all prescription drugs, over-the-counter medications, and supplements to their healthcare provider due to the potential for unknown drug interactions.

How should Butrum be stored and disposed of?

Official Storage and Disposal Requirements

Butrum (butorphanol) is a controlled substance requiring strict adherence to regulatory storage and disposal protocols.

Storage Component Official Requirement
Temperature Store at 20 C to 25 C (Controlled Room Temperature).
Protection Keep from freezing; protect the injectable solution from light and moisture.
Child Safety Mandatory to store the medication in a locked, secure location and out of the sight and reach of children.
Container Rule Keep the nasal spray unit in its child-resistant container when not in use.

Disposal must be immediate once the medicine is no longer needed or is outdated. Official regulatory instructions state that Butrum should be disposed of via a drug take-back program. If a take-back program is unavailable, specific label directions, such as those for rinsing and discarding the nasal spray components, must be followed to prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Butrum found in:

A-Z Index: